Kiran Patel - Concepedia

Author

Kiran Patel

Massachusetts General Hospital

Also Known As

Fran Lloyd, Karthik P Venkataraghavan, Kiran B Patel, Kiran Patel

Publications

7.1K

Citations

H-Index

Concepts

All Affiliations

Massachusetts General Hospital GlaxoSmithKline (United States)Regeneron (United States)Sanofi (France)Melanoma Institute Australia

About

Kiran Patel is an author at Massachusetts General Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	202
2	Health Sciences	2	2	37
3	Engineering	1	1	20
4	Nursing	1	1	11
5	Public Health	1	1	11

Kiran Patel

Publications

6.7K

Citations

H-Index

Page 1

	Year	Citations
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations Keith T. Flaherty, J. Infante, Adil Daud, New England Journal of Medicine	2012	2.8K
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, New England Journal of Medicine	2014	1.8K
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Axel Hauschild, Sanjiv S. Agarwala, Uwe Trefzer, Journal of Clinical Oncology	2009	540
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Journal of Clinical Oncology	2012	473
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis Evan S. Dellon, Marc E. Rothenberg, Margaret H. Collins, New England Journal of Medicine	2022	413
Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group David F. McDermott, Jeffrey A. Sosman, René González, Journal of Clinical Oncology	2008	249
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials Marcus Maurer, Thomas B. Casale, Sarbjit S. Saini, Journal of Allergy and Clinical Immunology	2024	110
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF<sup>V600E/K </sup>mutation-positive cutaneous melanoma Georgina V. Long, Daniil Stroyakovsky, Helen Gogas, Journal of Clinical Oncology First-line TherapyImmunologyPharmacotherapyImmunotherapeuticsDermatology	2014	69
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV Charlotte-Paige Rolle, Vu Cong Nguyen, Kiran Patel, Medicine	2021	49
Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies Lee S. Rosen, Bernadette Laxa, Leny Boulos, Clinical Cancer Research	2004	33

Page 1